(19)
(11) EP 3 245 302 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
19.01.2022 Bulletin 2022/03

(45) Mention of the grant of the patent:
14.07.2021 Bulletin 2021/28

(21) Application number: 16737859.5

(22) Date of filing: 14.01.2016
(51) International Patent Classification (IPC): 
C12Q 1/68(2018.01)
(52) Cooperative Patent Classification (CPC):
C12Q 2600/178; G16B 25/00; C12Q 1/6886; G16B 25/10; G16B 40/00; G16B 40/20; C12Q 2600/158
(86) International application number:
PCT/US2016/013353
(87) International publication number:
WO 2016/115312 (21.07.2016 Gazette 2016/29)

(54)

MIRNA-BASED PREDICTIVE MODELS FOR DIAGNOSIS AND PROGNOSIS OF PROSTATE CANCER

MIRNA-BASIERTE PRÄDIKTIVE MODELLE ZUR DIAGNOSE UND ZUR PROGNOSE VON PROSTATAKREBS

MODÈLES PRÉDICTIFS À BASE DE MICRO-ARN POUR LE DIAGNOSTIC ET LE PRONOSTIC DU CANCER DE LA PROSTATE


(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 14.01.2015 US 201562103288 P

(43) Date of publication of application:
22.11.2017 Bulletin 2017/47

(60) Divisional application:
21185398.1

(73) Proprietors:
  • Ohio State Innovation Foundation
    Columbus, OH 43201 (US)
  • Albert-Ludwigs-Universität Freiburg
    79098 Freiburg (DE)

(72) Inventors:
  • CHAKRAVARTI, Arnab
    Dublin, OH 43017 (US)
  • MCKENZIE BELL, Erica
    Columbus, OH 43212 (US)
  • KIRSTE, Simon
    79106 Freiburg (DE)
  • GROSU, Anca-Ligia
    79104 Freiburg (DE)

(74) Representative: Creek, Isobel Clare 
The IP Asset Partnership Limited Prama House 267 Banbury Road
Oxford OX2 7HT
Oxford OX2 7HT (GB)


(56) References cited: : 
WO-A1-2011/127219
WO-A1-2014/085906
WO-A2-2012/015765
US-A1- 2013 005 837
US-A1- 2014 309 130
WO-A1-2014/085906
WO-A2-2011/082198
US-A1- 2010 179 213
US-A1- 2013 053 264
   
  • R J BRYANT ET AL: "Changes in circulating microRNA levels associated with prostate cancer", BRITISH JOURNAL OF CANCER, vol. 106, no. 4, 14 February 2012 (2012-02-14), pages 768-774, XP055079507, ISSN: 0007-0920, DOI: 10.1038/bjc.2011.595
  • ANNIKA SCHAEFER ET AL: "Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma", INTERNATIONAL JOURNAL OF CANCER, 1 January 2009 (2009-01-01), pages NA-NA, XP055091557, ISSN: 0020-7136, DOI: 10.1002/ijc.24827
  • TAO LI ET AL: "miR-21 as an Independent Biochemical Recurrence Predictor and Potential Therapeutic Target for Prostate Cancer", THE JOURNAL OF UROLOGY, vol. 187, no. 4, 1 April 2012 (2012-04-01) , pages 1466-1472, XP055114090, ISSN: 0022-5347, DOI: 10.1016/j.juro.2011.11.082
  • BELL ET AL.: 'A Novel MiRNA-Based Predictive Model for Biochemical Failure Following Post- Prostatectomy Salvage Radiation Therapy' PLOS ONE vol. 10, no. 3, 11 March 2015, pages 1 - 19, XP055467452 DOI: 10.1371/JOURNAL.PONE.0118745
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).